Prestige BioPharma Limited

A950210

KR8702070002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
7,980 ^KRW	0.00%		-1.48%	-15.82%

2023	Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	CI
2023	Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	CI

Prestige BioPharma Limited(KOSE:A950210) added to S&P Global BMI Index

September 20, 2021 at 09:30 am IST

Latest news about Prestige BioPharma Limited

Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the Treatment of Pancreatic Cancer	21/23/21	CI
Prestige BioPharma Limited Develops First-In-Class PAUF-detecting Diagnostic Kit	09/23/09	CI
Prestige Biopharma Submits Pre-BLA Type 4 Meeting Request to FDA for Herceptin Biosimilar	14/22/14	CI
Prestige Biologics Co., Ltd. announced that it has received KRW 6.893915 billion in funding from Prestige BioPharma Limited	05/22/05	CI
Prestige Biologics Co., Ltd. announced that it expects to receive KRW 6.893915 billion in funding from Prestige BioPharma Limited	26/22/26	CI
Prestige Biopharma and Intas Pharmaceuticals Announce Partnership to Commercialize Bevacizumab Biosimilar in the Us, Europe, Canada, Mena, Brazil, Mexico, South Africa, Cis and the Sea Countries	26/22/26	CI
US FDA Approves Prestige Biopharma’s IND for Phase 1/2a Trial of First-in-Class Pancreatic Cancer Treatment, PBP1510	27/22/27	CI
Prestige Biopharma Enters MOU with Vaxine for Supply of COVID-19 Vaccine and Co-development of COVID-19/Influenza Combo Vaccine	29/22/29	CI
The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology	11/22/11	CI
Prestige BioPharma Limited Announces Preclinical Data of Pancreatic Cancer Treatment, PBP1510, Present in ESMO TAT 2022	08/22/08	CI
Prestige BioPharma Limited Commences Construction of Innovative Discovery Center in Busan, Korea	20/21/20	CI
Prestige BioPharma and Dr. Reddy’s Announce Partnership to Commercialize Trastuzumab Biosimilar in Select Countries in Latin America and Southeast Asia	09/21/09	CI
Prestige BioPharma Limited(KOSE:A950210) added to S&P Global BMI Index	20/21/20	CI

Chart Prestige BioPharma Limited

Duration

Period

More charts

Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008 and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and anti-tumor growth effects. IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1.

Sector

Pharmaceuticals

Calendar

17/09/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
PRESTIGE BIOPHARMA LIMITED	-15.82%	7.01Cr
CSL LIMITED	-1.57%	8.94TCr
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	4.07TCr
BIOGEN INC.	-12.32%	3.28TCr
UCB	+52.41%	2.5TCr
BIOMARIN PHARMACEUTICAL INC.	-17.39%	1.53TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	1.16TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	1.15TCr
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	898.19Cr
INNOVENT BIOLOGICS, INC.	-7.72%	822.67Cr

Biopharmaceuticals